In certain groups of men, glucose-6-phosphate dehydrogenase (G6PD) deficiency was linked with an increased likelihood of severe COVID-19, a Veterans Affairs cohort study found. In Black men under 65, ...

A COMMON enzyme found in mammals that kills damaged cells before they become cancerous is being hailed as an important breakthrough in understanding the treatment of the disease. Researchers from the ...

DURHAM, N.C. – Many people who undergo treatment for hepatitis C develop hemolytic anemia, a disorder that destroys red blood cells. In some cases, it is so severe they have to reduce their medication ...

Favism is a common hereditary disease, affecting around 400 million people worldwide. It is caused by a lack of the enzyme glucose-6-phosphate dehydrogenase (G6PD). This deficiency triggers the ...

Arcturus Therapeutics ((ARCT)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...

Editor’s note: Each week WRAL TechWire takes a deep dive into a particular company or technology or personality. Today it’s medtech. RESEARCH TRIANGLE PARK – Baebies, a medical device and diagnostics ...

The first-ever treatment for an extremely rare and often fatal genetic disease that interferes with the body’s ability to tap built-up stores of sugar for energy received federal approval Friday. The ...

An ultra-rare enzyme deficiency that keeps infants from achieving proper muscle function among other developmental delays now has its first FDA-approved treatment. The new product, a gene therapy ...